Trials / Completed
CompletedNCT00440128
The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects With Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effect of the study drug (GW679769) on a commonly used chemotherapy drug (docetaxel) which will be given I.V. Blood samples will be taken to see if the GW679769 alters the blood levels of the chemotherapy. The study will last about 2 weeks with a final follow-up visit 6 weeks later.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | Docetaxel |
| DRUG | Casopitant/Docetaxel | Casopitant/Docetaxel |
Timeline
- Start date
- 2007-05-04
- Primary completion
- 2008-07-17
- Completion
- 2008-07-17
- First posted
- 2007-02-26
- Last updated
- 2017-08-04
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00440128. Inclusion in this directory is not an endorsement.